Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1172.82 | -0.3% | 851.2K |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $268.21 | +0.9% | 4.3M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $443.4b | $256.17 | -0.8% | 2.4M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $315.6b | $148.18 | -0.8% | 5.6M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $263.1b | $162.15 | -1.1% | 1.2M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $212.2b | $623.00 | -1.4% | 314.4K |
 AMGN | Amgen Inc | Immunology & AutoimmuneRare Disease Therapeutics | $207.9b | $432.00 | -1.0% | 1.2M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $161.7b | $146.88 | -2.1% | 1.4M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $142.7b | $27.93 | -0.3% | 7.4M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $133.4b | $66.44 | -0.7% | 1.8M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $119.5b | $542.50 | -1.1% | 407.7K |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $78.2b | $796.03 | -1.7% | 369.6K |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $39.1b | $154.25 | -2.4% | 2.1M |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $38.7b | $260.36 | -0.2% | 442.1K |
 WAT | Waters Corp | Clinical-Stage Platforms | $36.8b | $414.61 | -1.6% | 350.8K |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $30.0b | $218.63 | -1.3% | 164.7K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $27.5b | $242.06 | +0.2% | 558.4K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $25.3b | $60.45 | -1.7% | 1.4M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $24.5b | $337.19 | -2.5% | 252.5K |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $24.2b | $123.83 | -2.6% | 579.3K |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $24.1b | $34.44 | -7.6% | 7.0M |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $22.0b | $136.41 | -3.4% | 5.2M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $21.9b | $515.50 | -2.3% | 211.6K |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $21.4b | $119.18 | -2.4% | 563.1K |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $16.9b | $155.00 | -1.2% | 322.7K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $16.0b | $600.12 | -1.9% | 156.7K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $16.0b | $247.95 | -0.5% | 144.4K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $15.9b | $248.09 | -2.6% | 1.1M |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $15.7b | $76.86 | -2.6% | 565.3K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $12.9b | $128.80 | -0.7% | 1.3M |
 ICLR | Icon Plc | Clinical-Stage Platforms | $12.6b | $175.14 | +0.1% | 255.4K |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $12.4b | $113.58 | -2.6% | 364.4K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $11.9b | $85.29 | -4.1% | 413.4K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.6b | $64.77 | -1.0% | 913.5K |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $11.2b | $72.35 | -0.2% | 483.9K |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $11.2b | $200.19 | -3.5% | 179.9K |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $11.2b | $292.50 | -1.7% | 239.8K |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.1b | $533.91 | -1.8% | 132.8K |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $10.5b | $72.50 | -7.4% | 1.2M |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $10.4b | $13.69 | -4.3% | 1.5M |
 APGE | Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $10.1b | $135.02 | +0.0% | 352.7K |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $10.1b | $355.81 | -1.6% | 112.2K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $9.8b | $103.09 | -1.5% | 1.1M |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.6b | $57.18 | -3.7% | 1.6M |
 AVTR | Avantor, Inc. | Clinical-Stage Platforms | $9.3b | $14.58 | -0.2% | 4.1M |
 CRNX | Crinetics Pharmaceuticals, Inc. | Rare Disease Therapeutics | $8.8b | $84.97 | +0.0% | 616.7K |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $8.7b | $43.62 | -1.4% | 638.4K |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $8.6b | $61.24 | -2.3% | 759.2K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $8.5b | $345.30 | -6.2% | 104.1K |
 PTGX | Protagonist Therapeutics, Inc | Immunology & AutoimmuneMetabolic & Cardiometabolic | $8.5b | $142.62 | -3.6% | 402.4K |